Lee's Pharmaceutical Holdings Limited (0950.HK)
HKD 1.3
(0.0%)
HKD 1.3
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 930.06 Million HKD | -1.0% |
| 2022 | 939.5 Million HKD | -24.58% |
| 2021 | 1.24 Billion HKD | 9.51% |
| 2020 | 1.13 Billion HKD | -2.17% |
| 2019 | 1.16 Billion HKD | 51.31% |
| 2018 | 768.48 Million HKD | 45.66% |
| 2017 | 527.59 Million HKD | 23.65% |
| 2016 | 426.68 Million HKD | 27.63% |
| 2015 | 334.3 Million HKD | -9.77% |
| 2014 | 370.51 Million HKD | 18.15% |
| 2013 | 313.59 Million HKD | 54.29% |
| 2012 | 203.25 Million HKD | 107.94% |
| 2011 | 97.74 Million HKD | 38.91% |
| 2010 | 70.36 Million HKD | 10.23% |
| 2009 | 63.83 Million HKD | 182.77% |
| 2008 | 22.57 Million HKD | -12.41% |
| 2007 | 25.77 Million HKD | 32.64% |
| 2006 | 19.43 Million HKD | 73.77% |
| 2005 | 11.18 Million HKD | -10.67% |
| 2004 | 12.51 Million HKD | -19.49% |
| 2003 | 15.54 Million HKD | 19.03% |
| 2002 | 13.06 Million HKD | -31.53% |
| 2001 | 19.07 Million HKD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 FY | 930.06 Million HKD | -1.0% |
| 2023 Q3 | 930.06 Million HKD | -7.1% |
| 2023 Q4 | 930.06 Million HKD | 0.0% |
| 2023 Q1 | 1 Billion HKD | 6.56% |
| 2023 Q2 | 1 Billion HKD | 0.0% |
| 2022 Q3 | - HKD | -100.0% |
| 2022 Q4 | 939.5 Million HKD | 0.0% |
| 2022 FY | 939.5 Million HKD | -24.58% |
| 2022 Q1 | - HKD | -100.0% |
| 2022 Q2 | 1.17 Billion HKD | 0.0% |
| 2021 FY | 1.24 Billion HKD | 9.51% |
| 2021 Q1 | - HKD | -100.0% |
| 2021 Q4 | 1.24 Billion HKD | 0.0% |
| 2021 Q2 | 1.14 Billion HKD | 0.0% |
| 2020 Q4 | 1.13 Billion HKD | 0.0% |
| 2020 Q1 | - HKD | -100.0% |
| 2020 Q2 | 1.18 Billion HKD | 0.0% |
| 2020 FY | 1.13 Billion HKD | -2.17% |
| 2019 Q1 | - HKD | -100.0% |
| 2019 FY | 1.16 Billion HKD | 51.31% |
| 2019 Q2 | 937 Million HKD | 0.0% |
| 2019 Q4 | 1.16 Billion HKD | 0.0% |
| 2018 Q2 | 758.69 Million HKD | 0.0% |
| 2018 FY | 768.48 Million HKD | 45.66% |
| 2018 Q1 | - HKD | -100.0% |
| 2018 Q4 | 768.48 Million HKD | 0.0% |
| 2017 Q1 | - HKD | -100.0% |
| 2017 FY | 527.59 Million HKD | 23.65% |
| 2017 Q4 | 527.59 Million HKD | 0.0% |
| 2017 Q2 | 439.39 Million HKD | 0.0% |
| 2016 FY | 426.68 Million HKD | 27.63% |
| 2016 Q1 | - HKD | -100.0% |
| 2016 Q2 | 392.16 Million HKD | 0.0% |
| 2016 Q4 | 426.68 Million HKD | 0.0% |
| 2015 FY | 334.3 Million HKD | -9.77% |
| 2015 Q2 | 358.04 Million HKD | 0.0% |
| 2015 Q4 | 334.3 Million HKD | 0.0% |
| 2015 Q1 | - HKD | -100.0% |
| 2014 Q1 | - HKD | -100.0% |
| 2014 Q4 | 370.51 Million HKD | 0.0% |
| 2014 FY | 370.51 Million HKD | 18.15% |
| 2014 Q2 | 312.42 Million HKD | 0.0% |
| 2013 Q1 | - HKD | -100.0% |
| 2013 FY | 313.59 Million HKD | 54.29% |
| 2013 Q4 | 313.59 Million HKD | 0.0% |
| 2013 Q2 | 206.01 Million HKD | 0.0% |
| 2012 FY | 203.25 Million HKD | 107.94% |
| 2012 Q2 | 157.24 Million HKD | 0.0% |
| 2012 Q4 | 203.25 Million HKD | 0.0% |
| 2011 FY | 97.74 Million HKD | 38.91% |
| 2011 Q2 | 77.07 Million HKD | 0.0% |
| 2011 Q4 | 97.74 Million HKD | 0.0% |
| 2010 Q2 | 51.47 Million HKD | 0.0% |
| 2010 FY | 70.36 Million HKD | 10.23% |
| 2009 FY | 63.83 Million HKD | 182.77% |
| 2008 FY | 22.57 Million HKD | -12.41% |
| 2007 FY | 25.77 Million HKD | 32.64% |
| 2006 FY | 19.43 Million HKD | 73.77% |
| 2005 FY | 11.18 Million HKD | -10.67% |
| 2004 FY | 12.51 Million HKD | -19.49% |
| 2003 FY | 15.54 Million HKD | 19.03% |
| 2002 FY | 13.06 Million HKD | -31.53% |
| 2001 FY | 19.07 Million HKD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 142.28 Million HKD | -553.68% |
| Grand Pharmaceutical Group Limited | 7.24 Billion HKD | 87.162% |
| Extrawell Pharmaceutical Holdings Limited | 170.4 Million HKD | -445.793% |
| Wai Yuen Tong Medicine Holdings Limited | 709.65 Million HKD | -31.06% |
| Qianhai Health Holdings Limited | 94 Million HKD | -889.404% |
| Essex Bio-Technology Limited | 903.78 Million HKD | -2.909% |
| Tongfang Kontafarma Holdings Limited | 665.38 Million HKD | -39.778% |
| PuraPharm Corporation Limited | 689.65 Million HKD | -34.861% |
| SSY Group Limited | 4.49 Billion HKD | 79.304% |
| JBM (Healthcare) Limited | 366.75 Million HKD | -153.595% |
| Jacobson Pharma Corporation Limited | 1.09 Billion HKD | 14.711% |
| China Resources Pharmaceutical Group Limited | 168.46 Billion HKD | 99.448% |